Patrícia Dias Carvalho

Ms. Patrícia Dias Carvalho

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Cancer Research
Verified
Journal Article
Open access
PDF file
PCPatrícia Dias Carvalho
Patrícia Dias Carvalho
CGCarlos Guimarães
Carlos Guimarães
ACAna Patrícia Cardoso
Ana Patrícia Cardoso
SMSusana Mendonça
Susana Mendonça
ACAngela Costa
Angela Costa
Sérgia VelhoSérgia Velho
Sérgia Velho
KRAS is one of the most frequently mutated oncogenes in cancer, being a potent initiator of tumorigenesis, a strong inductor of malignancy, and a predictive biomarker of response to therapy. Despite the large investment to understand the effects of KRAS activation in cancer cells, pharmacologic targeting of KRAS or its downstream effectors has not yet been successful at the clinical level. Recent studies are now describing new mechanisms of KRAS-induced tumorigenesis by analyzing its effects on the components of the tumor microenvironment. These studies revealed that the activation of KRAS on cancer cells extends to the surrounding microenvironment, affecting the properties and functions of its constituents. Herein, we discuss the most emergent perspectives on the relationship between KRAS-mutant cancer cells and their microenvironment components. Cancer Res; 78(1); 1–8. ©2017 AACR.

19 February 2018 in Cells
Verified
Journal Article
Open access
PDF file
GCGiulia Cazzanelli
Giulia Cazzanelli
FPFlávia Pereira
Flávia Pereira
SASara Alves
Sara Alves
RFRita Francisco
Rita Francisco
LALuisa Azevedo
Luisa Azevedo
Ana PretoAna Preto
Ana Preto
The exploitation of the yeast Saccharomyces cerevisiae as a biological model for the investigation of complex molecular processes conserved in multicellular organisms, such as humans, has allowed fundamental biological discoveries. When comparing yeast and human proteins, it is clear that both amino acid sequences and protein functions are often very well conserved. One example of the high degree of conservation between human and yeast proteins is highlighted by the members of the RAS family. Indeed, the study of the signaling pathways regulated by RAS in yeast cells led to the discovery of properties that were often found interchangeable with RAS proto-oncogenes in human pathways, and vice versa. In this work, we performed an updated critical literature review on human and yeast RAS pathways, specifically highlighting the similarities and differences between them. Moreover, we emphasized the contribution of studying yeast RAS pathways for the understanding of human RAS and how this model organism can contribute to unveil the roles of RAS oncoproteins in the regulation of mechanisms important in the tumorigenic process, like autophagy.

13 December 2019 in Cancers
Verified
Journal Article
Open access
PDF file
PCPatrícia Dias Carvalho
Patrícia Dias Carvalho
AMAna Luísa Machado
Ana Luísa Machado
FMFlávia Martins
Flávia Martins
Raquel SerucaRaquel Seruca
Raquel Seruca
Sérgia VelhoSérgia Velho
Sérgia Velho
Current evidence strongly suggests that cancer cells depend on the microenvironment in order to thrive. In fact, signals from the surrounding tumor microenvironment are crucial for cancer cells´ aggressiveness, altering their expression profile and favoring their metastatic potential. As such, targeting the tumor microenvironment to impair cancer progression became an attractive therapeutic option. Interestingly, it has been shown that oncogenic KRAS signaling promotes a pro-tumorigenic microenvironment, and the associated crosstalk alters the expression profile of cancer cells. These findings award KRAS a key role in controlling the interactions between cancer cells and the microenvironment, granting cancer a poor prognosis. Given the lack of effective approaches to target KRAS itself or its downstream effectors in the clinic, exploring such interactions may open new perspectives on possible therapeutic strategies to hinder mutant KRAS tumors. This review highlights those communications and their implications for the development of effective therapies or to provide insights regarding response to existing regimens.

5 March 2020
Verified
Book Chapter
Closed access
PDF file
NMNuno Miguel Mendes
Nuno Miguel Mendes
PCPatrícia Dias Carvalho
Patrícia Dias Carvalho
FMF. Martins
F. Martins
SMS. Mendonça
S. Mendonça
AMA. R. Malheiro
A. R. Malheiro
Sérgia VelhoSérgia Velho
Sérgia Velho

11 August 2022 in Cells
Verified
Journal Article
Open access
PDF file
PCPatrícia Dias Carvalho
Patrícia Dias Carvalho
SMSusana Mendonça
Susana Mendonça
FMFlávia Martins
Flávia Martins
Maria  OliveiraMaria Oliveira
Maria Oliveira
Sérgia VelhoSérgia Velho
Sérgia Velho
KRAS mutations have been shown to extend their oncogenic effects beyond the cancer cell, influencing the tumor microenvironment. Herein, we studied the impact of mutant KRAS on the modulation of the pro-tumorigenic properties of cancer-associated fibroblasts (CAFs), including α-SMA expression, TGFβ1 and HGF production, extracellular matrix components and metalloproteinases expression as well as collagen contraction and migration capacities. To do so, CCD-18Co normal-like colon fibroblasts were challenged with conditioned media from control and KRAS silenced colorectal cancer (CRC) cells. Our results showed that the mutant KRAS CRC cell-secreted factors were capable of turning normal-like fibroblasts into CAF-like by modulating the α-SMA expression, TGFβ1 and HGF production and migration capacity. Oncogenic KRAS played a secondary role as its silencing did not completely impair the capacity of CRC cells to modulate most of the fibroblast properties analyzed. In summary, our work suggests that mutant KRAS does not play a major role in controlling the CRC cell-secreted factors that modulate the behavior of fibroblasts. The fact that CRC cells retain the capacity to modulate the pro-tumorigenic features of fibroblasts independently of KRAS silencing is likely to negatively impact their response to KRAS inhibitors, thus standing as a putative mechanism of resistance to KRAS inhibition with potential therapeutical relevance.

21 June 2022 in Cells
Verified
Journal Article
Open access
PDF file
PCPatrícia Dias Carvalho
Patrícia Dias Carvalho
FMFlávia Martins
Flávia Martins
JCJoana Carvalho
Joana Carvalho
Maria  OliveiraMaria Oliveira
Maria Oliveira
Sérgia VelhoSérgia Velho
Sérgia Velho
Understanding how mutant KRAS signaling is modulated by exogenous stimuli is of utmost importance to elucidate resistance mechanisms underlying pathway inhibition failure, and to uncover novel therapeutic targets for mutant KRAS patients. Hence, aiming at perceiving KRAS-autonomous versus -non autonomous mechanisms, we studied the response of two mutant KRAS colorectal cancer cell lines (HCT116 and LS174T) upon KRAS silencing and treatment with rhTGFβ1-activated fibroblasts secretome. A proteomic analysis revealed that rhTGFβ1-activated fibroblast-secreted factors triggered cell line-specific proteome alterations and that mutant KRAS governs 43% and 38% of these alterations in HCT116 and LS174T cells, respectively. These KRAS-dependent proteins were localized and displayed molecular functions that were common to both cell lines (e.g., extracellular exosome, RNA binding functions). Moreover, 67% and 78% of the KRAS-associated proteome of HCT116 and LS174T cells, respectively, was controlled in a KRAS-non-autonomous manner, being dependent on fibroblast-secreted factors. In HCT116 cells, KRAS-non-autonomously controlled proteins were mainly involved in proteoglycans in cancer, p53, and Rap1 signaling pathways; whereas in LS174T cells, they were associated with substrate adhesion-dependent cell-spreading and involved in metabolic processes. This work highlights the context-dependency of KRAS-associated signaling and reinforces the importance of integrating the tumor microenvironment in the study of KRAS-associated effects.